Download presentation
Published byPenelope Singleton Modified over 9 years ago
1
ECOLE NATIONALE VETERINAIRE T O U L O U S E Rationale for the effective use of pharmacokinetics and pharmacodynamics in drug development P.L. Toutain Update: 09/10//2010
2
Objective of the presentation
To show non-kineticists that PK can be a very useful tool to document drug safety and efficacy To understand the meaning and utility of the main PK parameters
3
PHARMACOLOGY Clinical pharmacology Pharmacokinetics Pharmacodynamics
Study of drug in a clinical context Action of animal on drug Pharmacodynamics Action of drug on animal
4
Clinical trials vs. PK/PD trials
5
Dose titration PK/PD Black box Dose Response PK PD Response surrogate
Plasma concentration
6
Dose effect vs. concentration effect relationship
External dose EFFECT Internal dose DOSE AUC = (Dose/Cl) Less variance must be expected in the AUC/effect than in the dose/effect relationship
7
dose-effect vs. exposure- effect relationship for GnRH
LH response Monnoyer et a.l J vet pharmaco ther 2004
8
Acute toxicity of anticancer drugs human versus mouse
Dose Ratio External dose AUC Ratio Internal dose Frequency
9
Digoxin levels in toxic and nontoxic patients
* From smith TW and haber E. J clin invest 1970;49:
10
The concentration principle in drug development: Extrapolations
From in vitro to in vivo From experimental to target species
11
PK/PD: in vitro vs. in vivo
Response Plasma concentration Body Extrapolation in vitro in vivo In vitro Medium concentration effet Test system
12
PK/PD for antibiotics: extrapolation from in vitro to in vivo
Bactericidal effect Plasma AB concentration Body pathogen In vitro Medium AB concentration Agar/ MH Pathogen MIC Killing rate
13
The concentration principle in drug development: mechanistic approach
14
PK/PD: mechanistic approach
Response Dose Plasma concentration Response Dose Plasma concentration Drug receptor interaction Transduction System specificity Drug specificity, affinity & intrinsic efficacy
15
The concentration principle in drug development
Drug action is mediated via the time course of drug concentration at the site of action easy to demonstrate in vitro also true in vivo
16
The concentration principle in drug development
The direct assessment of drug concentration at the actual site of action is seldom possible but: the drug concentration in plasma often bears a proportional relation and plasma concentrations can be used instead of site concentration
17
Indications for measuring blood levels
To determine an optimal dosage regimen Dose Dosage interval Conditions of administration Route; site etc To guide dose adjustment
18
Dose vs. plasma concentration profile as independent variable
Clearance Time X Mass (no biological information) Concentration profile (biological information)
19
PK vs. PD variability i.e. the 2 main sources of variability
20
PK is a critical step in understanding drug response and improving efficacy: Why ?
Many factors of variation Interspecific Absorption Distribution Metabolism Elimination Dose Concentration Factors of variation more limited Species Diet Age Gender Diseases Environment (husbandry,…) EFFECTS
21
PK and PD variability well documented PK PD Effect BODY Dose Receptor
Plasma concentration well documented species food age sex diseases Generally ignored but usually more pronounced than PK variabilities (for a given species)
22
PK/PD variability for anti-inflammatory drugs
Coefficient of variation (%) PK PD Clearance Vss EC50 EC50 antipyretic anti-inflammatory Nimesulide Tolfenamic Ac Prednisolone T. Haake, 1997
23
Definition of the main pharmacodynamic drug properties
Efficacy Drug action, drug effect, drug response efficiency Potency Power Sensitivity Selectivity Specificity
24
The 3 structural parameters of the dose-effect relationship
Emax ED50 slope 1 1 Emax 1 1 2 2 Emax 2 2 shallow steep ED501 ED502 Sensitivity Potency Efficacy Range of useful concentrations Selectivity
25
Efficacy vs. potency and selectivity
Efficacy, potency and selectivity therapeutic effect side effect A B 100 Effect 80 Concentration A more potent than B A = B for efficacy B is preferable to A in a clinical context for its selectivity
26
PK/PD variabilitiy Consequence for dosage adjustment
Effect Dose BODY Receptor Plasma concentration Clinical covariables disease severity or duration pathogens susceptibility Kidney function Liver function ... Population approach
27
How to document variabilities
POPULATION PK/PD
28
Kinetic population vs. classical approach
Few (healthy) laboratory intensive yes narrow Population Many (patient) hospital sparse no no (but documented) large Subjects Location of study Sampling Subject homogeneity Controlled variable Inference space
29
What is the usefulness of PK
Drug discovery and development Drug submission Drug prescription A requirement for regulatory affairs A scientific tool R & D Drug monitoring Guidelines Scientific critical mass of the company Human medicine Very basic Can be very sophisticated
30
Usefulness of PK 1-Drug prescription
31
Drug candidates for Therapeutic Drug Monitoring (TDM)
Low therapeutic index No physiologic or therapeutic endpoints to guide dosage Pharmacokinetics vary widely between individuals Need to monitor adherence ?
32
Effect of adherence rate on outcome in HIV infected patients
From: Paterson DL, et al. Ann Intern Med 2000;133:21-30.
33
Usefulness of PK 2-Drug discovery
34
Drug discovery and PK Historically poor PK (40%) but much better now
The success rate of New Chemical Entities (NCE) is low (1/5000) The main reasons for failure were : unacceptable clinical efficacy Historically poor PK (40%) but much better now
35
Why compounds fail or slow down in development
36
Pharmacokinetics and combinatorial chemistry
Chemistry (thousands of compounds per day) High screen throughput using molecular and cellular systems Selection of putative active compound Are these compounds able to become a drug Yes, if PK properties are appropriate
37
Drug discovery strategies
Researchers have concentrated on maximizing potency and selectivity (specificity) against a biological target but a good candidate requires a balance of potency, safety and PK properties now: drug metabolism and PK in drug discovery process is accepted
38
Drug discovery strategies
Hit screening - screen large compound libraries to find molecule with a specific biological response and having a high potency Lead generation/ optimization - application of structure-activity relationship (SARs) to improve hits and produce leads and after optimization, to produce candidate
39
Position of in vitro and in vivo PK screen in the lead generation / optimization phases of the drug discovery process
40
Hits Leads optimized leads
Potency/selectivity screening Hits Leads optimized leads Re-synthesis In-vitro DMPK screens In vivo DMPK screens Development candidate Roberts S.A. Current opinion, Drug Disc. Dev. 2003,6: 66-80
41
Hierarchical in vitro screening sequences
Physiochemical analysis; measured or computed New compound(s) In vitro binding against target receptor In vitro binding against selectivity receptors Functional activity against target receptor In vitro intrinsic clearance in hepatocytes In vitro permeability in Caco-2 cells In vitro protein binding In vivo pharmacokinetic and pharmacodynamic evaluation Roberts S.A. Current opinion, Drug Disc. Dev. 2003,6: 66-80
42
Predictive models ADME processes
van de Waterbeemd & Gifford, Nature Reviews Drug Discovery 2, 192, 2003
43
Clearance Renal Hepatic Metabolic Biliary IR CYP450 Others
Polymorphism 1A2;2C9;2C19;2D6;3A4 Amino-acid Glucuronide CAR Inhibition Sulfate Induction AHR PXR
44
Pharmacokinetics and combinatorial chemistry
PK (clearance determination) is the bottleneck cocktail approach and cassette dosing Objectives 200 compounds per week for 2 scientists
45
PK as a scientific tool 1- Drug discovery 2- Preclinical development
drug or prodrug design rational screening of drug and prodrug 2- Preclinical development support for toxicology support for pharmacodynamics Dose titration Interspecific prediction New formulation 3- Clinical development
46
The drugability Some general rules to understand the differences between a pharmacologically active compound and a future marketed drugs synthetic route, molecular weight , solubility, lipophilicity, logP, rule of five, bioavailability, efficacy, specificity, toxicity, blood brain barrier
47
Molecular weight WDI: drugs with calculable properties
48
Possible Impacts of MW Size or molecular weight of a potential drug affects: stability, ease of synthesis? solubility, transport across membranes bioavailability Biliary excretion (interspecific differences) Safety (antigenicity) success in clinical trials FDA approval!
49
Lipophilicity and partitioning coefficient (logP & logD)
As a definition logP refers to the neutral form of the compound.
50
Lipophilicity - Hydrophilicity
Critical values for LogP > 6 : poor water solubility Bad dissolution Too long residence time in lipidic phases Drug Discovery Today, 1996, 1: 179
51
Lipophilicity - Hydrophilicity
Critical values for LogP -3 à 0 : good hydrophilicity and paracellular passage Slower rate of absorption than for the transcellular pathway (limited absorption area) Influence of the MW (if too high, absorption is decreased) < -3 : too polar and impossible to cross a membrane Drug Discovery Today, 1996, 1: 179
52
3-Regulatory pharmacokinetics
Usefulness of PK 3-Regulatory pharmacokinetics
53
Regulatory pharmacokinetics
Purpose Necessity to understand the role of regulatory authorities The role of the authorities is to ensure that marketed drug products are safe and effective The authority requires basic PK information to understand the features of the drug and factor variation
54
Regulatory pharmacokinetics
Safety Efficacy Clinical trials PD PK properties Quality Proofs are independent The clinical trial is not the "pathognomonic" proof of drug efficacy and safety
55
Regulatory pharmacokinetics
Guideline vs. science driven PK the PK guidelines were written to provide regulatory people with the minimal information required to make a judgment and not to provide companies with an optimal drug development procedure Some companies have forgotten the true purpose of PK studies and too often PK data appear to have been generated with a "checklist" for regulatory authorities in mind rather than a scientific approach to efficacy
56
In a company, is PK conducted as :
A regulatory requirement or For rationale drug development
57
If PK is scientifically conducted
10 critical PK and PD parameters should be determined for each new drug
58
Hierarchy of pharmacokinetic parameters
R & D Clearance Effective concentration range Extent of bioavailability Fraction of the available dose excreted unchanged Blood / plasma concentration ratio Half-life Toxic concentration Extent of protein binding Volume of distribution Rate of availability Regulatory Absorption Distribution Metabolism Elimination Benett, 1993
59
Hierarchy of pharmacokinetic parameters
R & D Independent Have a physiological meaning Clearance, distribution Regulatory affairs Hybrid Only descriptive t 1/2, Cmax, Tmax
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.